Taking people in SpainPhase 1
Tests budoprutug in adults with systemic lupus erythematosus
Tests budoprutug, an experimental drug, in adults with lupus affecting the whole body.
Key facts
- Who runs it
- Climb Bio Inc.
- Where
- A Coruña and Sabadell, SpainSee the 2 sitesAlso in 3 other countries, 6 sites
- Trial code
- Registry title
- A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 11 people, planned
- Started
- 26 Nov 2025
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Systemic Lupus Erythematosus to study how well and how safe budoprutug (TNT119) is.
- Age
- 18 years or older
- Sex
- All sexes can join
Where in Spain
Also in 3 other countries, 6 sites
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
- Parc Tauli Hospital UniversitariSabadell, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests budoprutug in adults with systemic lupus erythematosusGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 June 2026